Estados financieros detallados de ENDRA Life Sciences Inc. (NDRA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $5.30, NDRA presenta beneficios negativos (P/E no significativo) y un ROE del -310.93%. La capitalización bursátil es de $7M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $515582 | $351622 | $6174 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $235878 | $172782 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | $279704 | $178840 | $6174 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $495377 | $1.9M | $4.7M | $6.6M | $5.9M | $5.5M | $6.6M | $5.0M | $3.2M | $1.8M |
| Generales y Administrativos | $1.6M | $2.9M | $4.0M | $4.3M | $5.6M | $6.0M | $6.6M | $5.5M | $7.6M | $3.9M |
| Gastos Operativos | $2.1M | $4.8M | $9.0M | $10.8M | $11.5M | $11.5M | $13.2M | $10.5M | $10.8M | $5.8M |
| Beneficio Operativo | -$1.8M | -$4.6M | -$9.0M | -$10.8M | -$11.5M | -$11.5M | -$13.2M | -$10.5M | -$10.8M | -$5.8M |
| EBITDA | -$1.7M | -$4.6M | -$9.0M | -$10.8M | -$11.3M | -$11.0M | -$12.9M | -$9.8M | -$11.3M | -$6.9M |
| Gastos por Intereses | 0 | 0 | $729241 | $2.4M | $232426 | 0 | $21533 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$2.8M | -$5.4M | -$9.8M | -$13.3M | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$2.8M | -$5.4M | -$9.8M | -$13.3M | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| BPA | $-14.21 | $-27.47 | $-43.49 | $-41.48 | $-12.47 | $-5.47 | $-4.57 | $-5.89 | $-10.25 | $-8.93 |
| BPA Diluido | $-14.21 | $-27.47 | $-43.49 | $-41.48 | $-12.47 | $-5.47 | $-6.84 | $-5.89 | $-10.25 | $-8.93 |
| Acciones en Circulación (Diluidas) | $195351 | $195751 | $225243 | $374999 | $959611 | $2.0M | $1.9M | $1.7M | $1.1M | $787020 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $144953 | $5.6M | $6.5M | $6.2M | $7.2M | $9.5M | $4.9M | $2.8M | $3.2M | $762365 |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | $6850 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | $40105 | $191680 | $59444 | $113442 | $589620 | $1.3M | $2.6M | 0 | 0 | 0 |
| Activos Corrientes | $195593 | $5.9M | $6.9M | $6.5M | $8.2M | $12.1M | $8.5M | $3.0M | $3.4M | $967969 |
| Inmovilizado Material | $295168 | $241549 | $273233 | $641170 | $551254 | $774543 | $741471 | $465873 | $647294 | $504465 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $490761 | $6.1M | $7.2M | $7.2M | $8.8M | $12.9M | $9.3M | $6.8M | $4.5M | $3.9M |
| Cuentas por Pagar | $227743 | $780261 | $631472 | $1.3M | $402910 | $791052 | $613961 | $360401 | $269683 | $382970 |
| Deuda a Corto | $949976 | 0 | 0 | $364262 | $83870 | $117133 | $28484 | $28484 | $169720 | 0 |
| Pasivos Corrientes | $1.4M | $848214 | $974583 | $2.1M | $986663 | $1.5M | $1.7M | $903095 | $605230 | $750956 |
| Deuda a Largo | 0 | 0 | 0 | 0 | $337084 | $28484 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $1.4M | $848214 | $974583 | $2.4M | $1.6M | $2.1M | $2.1M | $1.1M | $1.9M | $1.6M |
| Reservas | -$12.5M | -$17.9M | -$27.7M | -$45.2M | -$57.3M | -$68.7M | -$81.9M | -$91.9M | -$103.4M | -$110.5M |
| Patrimonio Neto | -$893767 | $5.3M | $6.2M | $4.8M | $7.2M | $10.8M | $7.2M | $5.7M | $2.6M | $2.3M |
| Deuda Total | $949976 | 0 | $23 | $773267 | $769342 | $796094 | $546631 | $394403 | $754139 | $492352 |
| Deuda Neta | $805023 | -$5.6M | -$6.5M | -$5.4M | -$6.5M | -$8.7M | -$4.3M | -$2.4M | -$2.5M | -$270013 |
| Capital Circulante | -$1.2M | $5.0M | $6.0M | $4.5M | $7.2M | $10.6M | $6.8M | $2.1M | $2.8M | $217013 |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$2.8M | -$5.4M | -$9.8M | -$13.3M | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| Amortizaciones | $64936 | $61481 | $68316 | $115011 | $165249 | $224415 | $234258 | $275451 | $206172 | $157294 |
| Compensación en Acciones | $230326 | $1003 | $1368 | $1400 | $2.1M | $1.4M | $1.2M | $996430 | $571924 | $329409 |
| Cambio en Capital Circulante | $254981 | $298659 | -$359081 | $597830 | -$1.5M | -$1.3M | -$1.0M | -$923319 | $134079 | $22616 |
| Flujo de Caja Operativo | -$1.3M | -$3.3M | -$7.7M | -$8.6M | -$10.8M | -$11.1M | -$12.8M | -$9.5M | -$7.4M | -$5.2M |
| Inversiones (CapEx) | 0 | -$7862 | -$100000 | -$43595 | -$51333 | -$45000 | -$202577 | -$33884 | -$16000 | -$17280 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | -$4.2M | -$395551 | -$121071 | -$7790 | -$840 | -$5233 | 0 |
| Flujo de Caja Libre | -$1.3M | -$3.3M | -$7.8M | -$8.6M | -$10.8M | -$11.2M | -$13.0M | -$9.6M | -$7.4M | -$5.2M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -31.8% | -98.2% | -100.0% | |||||||
| Crecimiento Beneficio Neto (anual) | -93.7% | -82.2% | -35.8% | +11.9% | +4.2% | -17.3% | +23.7% | -14.4% | +38.9% | |
| Crecimiento BPA (anual) | -93.3% | -58.3% | +4.6% | +69.9% | +56.1% | +16.5% | -28.9% | -74.0% | +12.9% | |
| Cambio en Acciones (anual) | +0.2% | +15.1% | +66.5% | +155.9% | +113.2% | -5.7% | -11.5% | -34.3% | -29.9% | |
| Crecimiento FCF (anual) | -151.5% | -135.8% | -10.6% | -25.4% | -3.2% | -16.2% | +26.1% | +22.6% | +29.9% | |
| Margen Bruto | 54.3% | 50.9% | 100.0% | |||||||
| Margen Operativo | -347.5% | -1315.6% | -146080.5% | |||||||
| Margen EBITDA | -334.9% | -1298.1% | -145751.6% | |||||||
| Margen Neto | -538.3% | -1529.2% | -158669.6% | |||||||
| Margen FCF | -255.2% | -941.0% | -126376.4% | |||||||
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-6.73 | $-16.90 | $-34.64 | $-23.02 | $-11.28 | $-5.46 | $-6.72 | $-5.61 | $-6.61 | $-6.61 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $11.25 | $0.41 | $0.06 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $195351 | $195751 | $225243 | $374999 | $959611 | $2.0M | $1.9M | $1.7M | $1.1M | $787020 |
Qué mirar en Salud / Farma
El pipeline de I+D es el activo invisible. Patentes que caducan = ingresos que evaporan. Mira innovación y flujo de caja.
- I+D / Ingresos — Indica inversión en pipeline futuro. Farma seria reinvierte 15-20%
- Crecimiento EPS 5y — Tras caducidad de patentes, ¿siguen creciendo?
- Margen bruto — Farma de marca >70%. Genéricos mucho más bajo — define el tipo de negocio
- FCF / Net Income — Calidad del beneficio — farma grande debería convertir >90%
- ROIC — Capital reinvertido con eficiencia — clave en farma por ciclos de I+D largos
- Deuda neta / EBITDA — Adquisiciones de farma generan mucha deuda — ojo al post-M&A
- P/E vs historial 10y propio — La mejor comparación es con su propia historia, no con competidores
Rentabilidad
| Rentabilidad sobre capital | -310.93% |
| Rentabilidad sobre capital invertido | -178.30% |
| Rentabilidad sobre activos | -182.35% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.07 |
| Ratio corriente | 7.10 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -43.65 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -9605.91 | -6192.59 | -1207.17 | -1417.55 | -2105.05 | -4426.51 | -1558.53 | -629.88 | -0.61 | -0.51 |
| P/VC | -29834.86 | 6312.08 | 1892.58 | 4631.69 | 3513.55 | 4594.02 | 1908.36 | 1119.73 | 2.74 | 1.58 |
| P/V | 51719.05 | 94701.98 | 1915331.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 54.3% | 50.9% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | -347.5% | -1315.6% | -146080.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | -538.3% | -1529.2% | -158669.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: BBLG · BGMS · BNBX · DHAI · GCTK · HSCS · ISPC
Explorar sector: Healthcare · Medical - Diagnostics & Research
Más secciones de NDRA: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones